Allogeneic cell therapy to be tested for stroke

Thursday 21 April 2011

The Stanford University School of Medicine, together with privately-held SanBio Inc, have started a Phase 1/2a trial of an allogeneic cell therapy on patients with stable deficits resulting from a stroke.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States